More than two dozen of the world's largest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., have agreed to provide funding and other support to Interpol's battle against counterfeit prescription drugs.
Eli Lilly and Co. and five other big drugmakers avoided paying $7 billion in U.S. taxes last year by shifting their profits overseas. The strategy has drawn the ire of some legislators.
Eli Lilly and Co. has sued Roche Holding AG’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases.
Researchers suspect the sex hormone known to increase libido and musculature could also play a role in preventing a form of diabetes that tends to strike later in life and afflicts more than 330 million people worldwide.
Diagnostic products maker Qiagen NV said Wednesday that it will work with Eli Lilly and Co. to develop new tests that could identify patients who could be helped by Lilly’s drugs.
Eli Lilly said it is halting testing of experimental drug tabalumab because the studies show the medicine is not effective. The company said it expects to take a $50 million charge in the first quarter related to the research expenses from the drug.
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
Price increases and sales gains helped Eli Lilly and Co. offset declining revenue from its former blockbuster Zyprexa in the fourth quarter, allowing the company to beat analysts' expectations and raise its 2013 profit forecast.
Researchers have chosen an experimental drug by Eli Lilly and Co. for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it.
The value of Lilly Endowment Inc.’s principal holding—Eli Lilly and Co. stock—has increased nearly $2 billion over the past two years, bolstering the private foundation’s philanthropic firepower after a decade of declining or stagnant assets.
European regulators approved the use of an imaging agent from Eli Lilly and Co., which can help doctors diagnose Alzheimer's disease.
Johnson & Johnson, the world’s largest seller of health-care products, won the backing of U.S. advisers for a diabetes pill the company is seeking to make the first in a new family of drugs for managing blood sugar.
Four sisters who claimed their breast cancer was caused by a drug their mother took during pregnancy in the 1950s reached a settlement Wednesday with Eli Lilly and Co. in the first of scores of similar claims around the country to go to trial.
In opening statements Tuesday, a lawyer for Indianapolis-based Lilly told the jury there is no evidence the synthetic estrogen known as DES causes breast cancer in the daughters of women who took it.
Pharmaceutical companies including Pfizer Inc., Bristol-Myers Squibb Co. and Eli Lilly and Co. could be ready to start making major acquisitions again.
Eli Lilly and Co. forecasts its 2013 earnings will grow more than Wall Street expects even though the drugmaker will lose U.S. patent protection for two more key products in the new year.
Four sisters diagnosed with breast cancer are suing Eli Lilly and Co., a former maker of DES, or diethylstilbestrol, a drug taken by their mother in the 1950s when she was pregnant. It could be the first of scores of such trials over the drug.
According to a statement released by the SEC, Eli Lilly paid $6.5 million—and in some cases gave jewelry and spa treatments—to win government contracts in Brazil, China, Russia and Poland.
Indianapolis-based drugmaker Eli Lilly and Co. said Monday that its board authorized a $1.5 billion share-repurchase program, which the company expects to complete next year.
Eli Lilly and Co. suffered a delay in its effort to bring an Alzheimer’s drug to market this month, but it also published new research that the pharmaceutical company thinks confirms it is on the right track.
